JP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Vera Therapeutics (NASDAQ:VERA) but lowers the price target from $65 to $62.
August 13, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Vera Therapeutics but lowers the price target from $65 to $62.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100